PMID- 29234328
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 8
DP  - 2017
TI  - Forward and Reverse Signaling Mediated by Transmembrane Tumor Necrosis 
      Factor-Alpha and TNF Receptor 2: Potential Roles in an Immunosuppressive Tumor 
      Microenvironment.
PG  - 1675
LID - 10.3389/fimmu.2017.01675 [doi]
LID - 1675
AB  - Tumor necrosis factor-alpha (TNF-alpha) is a pleiotropic inflammatory cytokine 
      produced mainly by activated macrophages, lymphocytes and other cell types. Two 
      distinct forms of TNF-alpha have been identified: soluble TNF-alpha (sTNF-alpha) and 
      transmembrane TNF-alpha (mTNF-alpha). mTNF-alpha, which is the precursor of sTNF-alpha, can be 
      cleaved by the TNF-alpha converting enzyme (TACE) and is released as sTNF-alpha. sTNF-alpha 
      binds primarily to TNF receptor 1 (TNFR1) and plays an important role in the 
      inflammatory immune response, whereas mTNF-alpha interacts primarily with TNF 
      receptor 2 (TNFR2) and mediates the promotion of cellular proliferation and 
      survival and other biological effects. It has been reported that the interaction 
      between mTNF-alpha and TNFR2 induces bi-directional (forward and reverse) signaling 
      in both mTNF-alpha- and TNFR2-expressing cells. Increasing evidence shows that the 
      forward and reverse signaling mediated by mTNF-alpha and TNFR2 might play a 
      significant role in the tumor microenvironment. In this review, the role of the 
      crosstalk between mTNF-alpha and TNFR2 in the tumor microenvironment will be 
      discussed.
FAU - Qu, Yang
AU  - Qu Y
AD  - Department of Gastrointestinal Cancer Biology, Tianjin Medical University Cancer 
      Institute and Hospital, Tianjin, China.
AD  - Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
AD  - National Clinical Research Center for Cancer, Tianjin, China.
FAU - Zhao, Gang
AU  - Zhao G
AD  - Department of Gastrointestinal Cancer Biology, Tianjin Medical University Cancer 
      Institute and Hospital, Tianjin, China.
AD  - Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
AD  - National Clinical Research Center for Cancer, Tianjin, China.
FAU - Li, Hui
AU  - Li H
AD  - Department of Gastrointestinal Cancer Biology, Tianjin Medical University Cancer 
      Institute and Hospital, Tianjin, China.
AD  - Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
AD  - National Clinical Research Center for Cancer, Tianjin, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171128
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC5712345
OTO - NOTNLM
OT  - TNF receptor 2
OT  - forward signaling
OT  - reverse signaling
OT  - transmembrane tumor necrosis factor-alpha
OT  - tumor microenvironment
EDAT- 2017/12/14 06:00
MHDA- 2017/12/14 06:01
PMCR- 2017/01/01
CRDT- 2017/12/14 06:00
PHST- 2017/08/19 00:00 [received]
PHST- 2017/11/14 00:00 [accepted]
PHST- 2017/12/14 06:00 [entrez]
PHST- 2017/12/14 06:00 [pubmed]
PHST- 2017/12/14 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2017.01675 [doi]
PST - epublish
SO  - Front Immunol. 2017 Nov 28;8:1675. doi: 10.3389/fimmu.2017.01675. eCollection 
      2017.